•
Pinetree Therapeutics Inc., a Massachusetts-based biotechnology company, has announced the signing of an exclusive option and global licensing agreement with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN). The deal focuses on a preclinical epidermal growth factor receptor (EGFR) degrader candidate. According to the agreement, Pinetree will receive an initial payment of…